<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155635</url>
  </required_header>
  <id_info>
    <org_study_id>C-417</org_study_id>
    <nct_id>NCT01155635</nct_id>
  </id_info>
  <brief_title>Carvedilol Post-intervention Long-term Administration in Large-scale Trial</brief_title>
  <acronym>CAPITAL-RCT</acronym>
  <official_title>Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year
      clinical outcomes in patients with ST-segment elevation acute myocardial infarction and
      preserved left ventricular ejection fraction after primary percutaneous coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta-blocker therapy is recommended after ST-segment elevation acute myocardial infarction
      (STEMI) in the current guidelines although its efficacy in those patients who have undergone
      primary percutaneous coronary intervention (PCI) has not been adequately evaluated. The
      purpose of this study is to evaluate whether beta-blocker, carvedilol improves 6-year
      clinical outcomes in patients with STEMI and preserved left ventricular ejection fraction
      after primary PCI. The design of this study is multicenter, open-label, randomized controlled
      trial enrolling 1300 patients without any exclusion criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6-year</time_frame>
    <description>Death from any reason</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of death, myocardial infarction, acute coronary syndrome, heart failure hospitalization</measure>
    <time_frame>6-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden cardiac death</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndrome</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained ventricular tachycardia or ventricular fibrillation</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure hospitalization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>6-year</time_frame>
    <description>Stent thrombosis defined by Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-vessel revascularization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven target-lesion revascularization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any coronary revascularization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any clinically-driven coronary revascularization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery bypass grafting</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6-year</time_frame>
    <description>Any ischemic and hemorrhagic strokes excluding transient ischemic attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening of angina due to coronary spasm</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>6-year</time_frame>
    <description>Bleeding complications defined by GUSTO and TIMI definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any coronary revascularization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death, myocardial infarction, acute coronary syndrome, heart failure hospitalization</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death, myocardial infarction, stroke</measure>
    <time_frame>6-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Beta-blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Carvedilol with any dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Beta-blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No use of Carvedilol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Use of Carvedilol with any dose</description>
    <arm_group_label>Beta-blocker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Carvedilol</intervention_name>
    <description>No use of Carvedilol</description>
    <arm_group_label>Non Beta-blocker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with STEMI after primary PCI

          -  Patients with left ventricular ejection fraction more than or equal to 40%

        Exclusion Criteria:

          -  Patients with left ventricular ejection fraction less than 40%

          -  Patients with contraindication for beta-blocker

          -  Patients with implantable cardioverter defibrillators

          -  Patients with end-stage malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>June 25, 2017</last_update_submitted>
  <last_update_submitted_qc>June 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

